Eric Hughes Sells 9,533 Shares of Teva Pharmaceutical Industries (NYSE:TEVA) Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) insider Eric Hughes sold 9,533 shares of the stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $31.67, for a total transaction of $301,910.11. Following the completion of the sale, the insider directly owned 107,711 shares in the company, valued at approximately $3,411,207.37. This trade represents a 8.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA traded up $0.39 on Monday, hitting $31.44. The stock had a trading volume of 11,093,245 shares, compared to its average volume of 9,695,220. The company’s 50-day moving average is $33.01 and its two-hundred day moving average is $26.32. Teva Pharmaceutical Industries Ltd. has a one year low of $12.47 and a one year high of $37.35. The stock has a market cap of $36.15 billion, a price-to-earnings ratio of 26.20, a P/E/G ratio of 10.39 and a beta of 0.72. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.31. The company had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The business’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.71 earnings per share. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several hedge funds have recently modified their holdings of the company. Global Retirement Partners LLC raised its stake in shares of Teva Pharmaceutical Industries by 27.3% in the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock worth $42,000 after buying an additional 292 shares in the last quarter. Captrust Financial Advisors boosted its stake in Teva Pharmaceutical Industries by 2.1% during the fourth quarter. Captrust Financial Advisors now owns 14,715 shares of the company’s stock valued at $459,000 after buying an additional 302 shares in the last quarter. Banque Cantonale Vaudoise boosted its stake in Teva Pharmaceutical Industries by 6.3% during the fourth quarter. Banque Cantonale Vaudoise now owns 5,133 shares of the company’s stock valued at $160,000 after buying an additional 306 shares in the last quarter. Ethic Inc. grew its holdings in Teva Pharmaceutical Industries by 1.8% during the fourth quarter. Ethic Inc. now owns 18,127 shares of the company’s stock worth $566,000 after acquiring an additional 325 shares during the period. Finally, Allworth Financial LP grew its holdings in Teva Pharmaceutical Industries by 53.8% during the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after acquiring an additional 329 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on TEVA. Jefferies Financial Group boosted their price target on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Barclays lifted their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an “overweight” rating in a research note on Friday, January 30th. JPMorgan Chase & Co. upped their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a report on Tuesday, December 16th. Scotiabank increased their target price on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research report on Thursday, January 29th. Finally, Truist Financial boosted their price target on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and a consensus target price of $37.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.